Market Research Blog

Get Sample of the Report : https://www.futuremarketinsights.com/reports/sample/rep-gb-10376

Advancement and growing researches in the medical industry leads to a dramatic surge in the availability of new cancer treatment options. Radiation therapies and targeted therapy is showing significant promise in cancer treatment. For example, peptide receptor radionuclide therapy (PRRT) had recently approved the neuroendocrine tumors and projecting significant growth in the cancer treatment market. Peptide receptor radionuclide therapy (PRRT) is radioisotope or molecular therapy used to treat neuroendocrine tumors (NETs). Peptide receptor radionuclide therapy (PRRT) is recommended for the somatostatin receptor-positive gastroenteropancreatic NETs affected patients. Peptide receptor radionuclide therapy (PRRT) is a targeted therapy designed to slow the progression of gastroenteropancreatic NET and limiting radiation exposure to healthy tissue.

Lutathera (lutetium Lu 177 Oxodotreotide) was the first drug approved for the peptide receptor radionuclide therapy (PRRT) for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). In September 2017, the European Commission approved Lutathera peptide receptor radionuclide therapy (PRRT) drug manufactured by Advanced Accelerator Applications S.A. Although, the U.S. Food and Drug Administration (FDA) was approved LUTATHERA in January 2018. Growing clinical trials and development activities to create therapeutic radiopharmaceuticals expected to surge the growth of the peptide receptor radionuclide therapy (PRRT) market over the forecast period.

Peptide Receptor Radionuclide Therapy (PRRT) Market: Drivers and Restraints-

Increasing prevalence of the neuroendocrine tumors expected to impel the demand for peptide receptor radionuclide therapy (PRRT) as an increasing number of the patient pool. Establishment of reimbursement policies for Lutathera favors the demand for peptide receptor radionuclide therapy (PRRT). A temporary insurance/billing code was used for the peptide receptor radionuclide therapy (PRRT) till 2018. Moreover, increasing clinical trials for the new radiopharmaceuticals drugs approval for cancer therapy expected to surge the growth of the peptide receptor radionuclide therapy (PRRT) market. Increasing government and private organizations funding for cancer drugs and therapy development is another major factor expected to propel the growth of the peptide receptor radionuclide therapy (PRRT) market. Moreover, growing manufacturer’s interest in the radiopharmaceutical and cancer market flourish the growth of the peptide receptor radionuclide therapy (PRRT) market. Side effects such as the transient decrease in blood counts, nausea and others associated with PRRT expected to hamper the growth of the peptide receptor radionuclide therapy (PRRT) market.

Peptide Receptor Radionuclide Therapy (PRRT) Market: Overview

Peptide receptor radionuclide therapy (PRRT) a special type of radiopharmaceutical which injected into the patients’ bloodstream. This radiopeptide travels and binds to neuroendocrine tumor cells and provide a high dose of radiation directly to the cancer cell. Big pharmaceutical market players are focusing to enter in the radiopharmaceutical market. For instance, In October 2017, Novartis AG acquired Advanced Accelerator Applications (AAA) for $3.9 billion to expand oncology portfolio. This acquisition was valuable for Lutathera radiopharmaceutical candidates which were under FDA review in 2018.

Peptide Receptor Radionuclide Therapy (PRRT) Market: Region-wise Outlook

North America and Europe region are expected to grebe more than half of the market share for peptide receptor radionuclide therapy. Increasing clinical trials for radiopharmaceuticals and growing demand for the targeted therapy for cancer are the major factors driving the growth of the peptide receptor radionuclide therapy market in the U.S. and European countries. The Asia pacific peptide receptor radionuclide therapy market expected to grow with significant growth rate as growing demand for advance treatment option and comparatively high prevalence of cancer in India and China.

Peptide Receptor Radionuclide Therapy (PRRT) Market: Key Market Participants

Example of some market players participants in global peptide receptor radionuclide therapy (PRRT) market find across the value chain are Advanced Accelerator Applications (AAA) (Novartis AG) and others.

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to market segments such as geographies, application, and industry.

The report covers exhaust analysis on:

• Market Segments
• Market Dynamics
• Market Size
• Supply & Demand
• Current Trends/Issues/Challenges
• Competition & Companies involved
• Technology
• Value Chain

Regional analysis includes:

• North America (U.S., Canada)
• Latin America (Mexico. Brazil)
• Western Europe (Germany, Italy, France, U.K, Spain)
• Eastern Europe (Poland, Russia)
• Asia Pacific (India, China ASEAN, Australia & New Zealand)
• Japan
• Middle East and Africa (GCC Countries, S. Africa, Northern Africa)

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

Ask For Regional Data : https://www.futuremarketinsights.com/ask-regional/rep-gb-10376

Peptide Receptor Radionuclide Therapy (PRRT) Market: Segmentation

Get Sample of the Report : https://www.futuremarketinsights.com/reports/sample/rep-gb-10249

Antimicrobial Peptides Market: Drivers and Restraints

The cost of manufacturing antimicrobial peptides is more than the cost of manufacturing other pharmaceuticals for therapeutic utility depending on the target specificity. The business model for antimicrobial peptides is different than what is present in the pharmaceutical market owing to the novelty of the assays and techniques implemented.

The research process and designing the therapy process for commercialization is different, moreover the industry requires a more vigorous approach in order to create an entry and further access to the developing markets. Manufacturers of the antimicrobial peptides dependent therapy spend the majority their resources on upgrading the associated technology. The opportunities present in developing antimicrobial peptides are more as compared to threats prevalent. The application of antimicrobial peptides in ailment of Hepatitis C, pneumonia, bacterial infections, HIV AIDS and cancer is expected to surge the acceptance towards the therapies. The institutional research is heavily invested with rising pool of scientists and skilled technocrats interested in the domain for novel drugs involving antimicrobial peptides for rare diseases. The one of the pluses that include are antimicrobial peptides can be developed for a range of utilities ranging from increasing the shelf-life in food packaging to delivery of bioactive compounds in therapeutic sectors driving the market. The growing antibiotic resistance, synthetic approaches, innovative formulations and drug delivery routes are the factors expected to drive the growth.

Antimicrobial Peptides Market: Overview

The global market for antimicrobial peptides is estimated to experience a significant growth due to the increase in awareness and access towards drugs and therapies involving antimicrobial peptides. Chronic diseases where antibiotic resistance is not fruitful creates a more lucrative opportunity for manufactures present in the antimicrobial peptides market. The current structure of the antimicrobial peptides market include drugs targeted towards pneumonia, Hepatitis C, HIV and bacterial infections. Each of the antimicrobial peptides uses different type of mechanism and are used to deliver better clinical results.

Antimicrobial Peptides Market: Regional Outlook

Geographically, the Antimicrobial Peptides market is segmented into seven regions viz. South Asia, East Asia, Europe, Latin America, North America, Oceania and Middle East and Africa. Each country is equally important to drive the market for antimicrobial peptides, advanced or emerging healthcare settings help in restoring the market and increase the reach to a wider section of patients in need. The distribution channel is an important part for antimicrobial peptides; the developed markets focus on the applications wherein the antimicrobial resistance is compromised whereas the emerging markets are more focused towards the reach and affordability of antimicrobial peptides. The North America region is estimated to have a significant share in the antimicrobial peptides market, owing to its quality infrastructure supporting the need of antimicrobial peptides research activities undertaken. It is followed by Europe, East Asia and Oceania. The South Asia antimicrobial peptides market would translate as a lucrative market opportunity for manufacturers, as well as industry experts, with present change in adoption and growth in general pharmaceutical market.

The key players involved in the market of antimicrobial peptides market include Eli Lilly and Company, Pfizer Inc., GlaxoSmithKline plc, Novartis International AG, EnBiotix Inc., Johnson & Johnson Services, Merck & Co., Alexion Pharmaceuticals, Inc., Melinta Therapeutics, Inc., and Vertex Pharmaceuticals, Inc. The present market structure of antimicrobial peptides is expected to change with efforts and research present in clinical phase.

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments.

Ask For Regional Data : https://www.futuremarketinsights.com/ask-regional/rep-gb-10249

The report also maps the qualitative impact of various market factors on market segments and geographies.

• Market Segments
• Market Dynamics
• Market Size
• Supply & Demand
• Current Trends/Issues/Challenges
• Competition & Companies involved
• Technology Matrix
• Value Chain

Regional analysis of the Antimicrobial Peptides market report includes

• North America
• Latin America
• Europe
• South  Asia
• East Asia
• Oceania
• Middle East and Africa

Antimicrobial Peptides Market: Segmentation

Tentatively, the global antimicrobial peptides market has been segmented on the basis of ailments, distribution channel, route of administration and geography.

Get Sample of the Report : https://www.futuremarketinsights.com/reports/sample/rep-gb-10246

Retinal gene therapy is performed for inherited retinal diseases. Gene therapy can improve the vision impairment caused by mutation in RPE65 gene.  The recently launched retinal gene therapy, Luxturna, is being used for patient with Leber congenital amaurosis type 2, it is a form of inherited disease which causes impaired vision at birth leading to a more progressive degeneration. There are many retinal gene therapy clinical trials present at the moment using recombinant viruses.

Retinal Gene Therapy Market: Drivers and Restraints

Retinal gene therapy is projected to grow at an enormous rate. Retina is a desirable target for gene therapy, it is growing because of it being an irreplaceable part of human body. Retinal gene therapy market is expected to experience new entrants, with promising candidates in clinical phases of drug approval.

The market is expanding exponentially over the last year, with many drugs in ongoing clinical trials. Currently, retinal gene therapy market have only one FDA approved product, Luxturna from Spark Therapeutics. The product received FDA approval in year 2017, starting an era of possible retinal gene therapy. Recently it was announced that Roche is interested in purchasing the company for approximately US$ 4.8 Bn, the interests from leading pharmaceutical manufacturers highlight the potential within this retinal gene therapy market. The market is influenced with a high prevalence of Stargardt disease, a common type of inherited retinal dystrophies, prevalence of around 1 in 12,000. Accurate and early diagnosis can lead to a better market structure, with patients willing to enrol in the clinical trials process. More number of approved products can lead to a more convenient reach for patients.

The availability of the approved therapy is also minimal in emerging economies, if available, emerging countries can be the most attractive segments in terms of value addition. Qualified surgeons and standard infrastructure is required for retinal gene therapy procedures, it involves a surgical and delivery plan with great precision. Socio-economic condition can lead to the late entry of such modality in emerging countries. But, if treatment is present for a previously stated incurable disorder, it should reach out to as many as possible. Cost associated with the retinal gene therapy is considerably high as observed in other gene therapy procedures. The cost of retinal gene therapy is estimated to be around US$ 450,000 to US$ 850,000 in the US

Retinal Gene Therapy Market: Overview

The global market for retinal gene therapy would expand with the emergence of new manufacturers and better technological advances. Retinal gene therapy is favoured to become the standard treatment, given the advantages with eye it has been at the forefront of translation research of gene therapy. The research initiatives for retinal gene therapy date back to the mid-1990s. The success of the very first retinal gene therapy will be replicated by other entrants, it just require a planned clinical trial platform for human testing to observe the level of expression achieved.

Retinal Gene Therapy Market: Regional Wise Outlook

Geographically, the retinal gene therapy market is segmented into seven regions viz. South Asia, East Asia, North America, Latin America, Oceania, Europe, and Middle East and Africa. The North America retinal gene therapy market is the leader in the concerned global retinal gene therapy market. The only product approved is from a US based manufacturer, which reflects to the current market share for North America. The retinal gene therapy is also available in Europe from Spark Therapeutics. The deal is such that Novartis has exclusive rights to commercialize and distribute “Luxturna” in Europe and in all other countries outside the US, when regularized for use. So, clearly the current market for retinal gene therapy is consolidated in these two region.

The only player involved in this market of retinal gene therapy is Spark Therapeutics, Inc. The present market structure of retinal gene therapy is expected to change with efforts and research present in clinical phase.

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments

Ask For Regional Data : https://www.futuremarketinsights.com/ask-regional/rep-gb-10246

The report also maps the qualitative impact of various market factors on market segments and geographies.

• Market Segments
• Market Dynamics
• Market Size
• Supply & Demand
• Current Trends/Issues/Challenges
• Competition & Companies involved
• Technology Matrix
• Value Chain

Regional analysis of the Retinal Gene Therapy market report includes

• North America
• Latin America
• Europe
• South  Asia
• East Asia
• Oceania
• Middle East and Africa

Retinal Gene Therapy Market: Segmentation

Tentatively, the global retinal gene therapy market has been segmented on the basis of product type, end user and geography.

The veterinary syringes are driving the market due to its performance and increasing healthcare needs of veterinary animals. With improvements in the technologies Veterinary Syringes have become easy to use. Also they require less stress to animal keepers and provide accurate and quick results. Use of Veterinary Syringes help in managing various diseases by accurate dosing of the drugs. Also diet, exercise and regular veterinary checkups are important to improve the health of animals. With the rising adoption and increasing research & development and continuous efforts by the manufactures, the growth of Veterinary Syringes is expected to grow in the future.

Get Sample of the Report : https://www.futuremarketinsights.com/reports/sample/rep-gb-10238

Factors driving Veterinary Syringes Market

Veterinary Syringes are expected to drive the market with the increasing pet ownership and growing veterinary practices. According to the American Pet Products Manufactures Association (APPMA), United States holds 68% for pet ownership, which is expected to increase the market for veterinary syringes market. The use of syringes and medicines ensure healthy and long lives for pets.

Advancement in the technology has led to selection of animal health dosing syringes based on their size and treatment. Also increasing prevalence rate of diabetes in animals will increase the veterinary syringes market. However poorly injected products may not absorb properly in the body of animals and cause scar tissue, animal pain.

Also these veterinary syringes are inexpensive. To control diabetes successful therapy of insulin is required with accurate dosing which requires usage of veterinary syringes this is expected to further increase the demand for Veterinary Syringes. According to the American pet society approximately 1 in 300 adult dogs and 1 in 230 cats in the US are suffering from diabetes which will also drive the Veterinary Syringes market.

Geographically, the Veterinary Syringes Market is segmented into various regions such as Europe, North America, Asia-Pacific, Latin America, Japan and Middle East & Africa. United States in North America is expected to dominate the Veterinary Syringes Market globally, followed by Europe, due to increasing adoption of companion animals in the region. Further, the availability of advanced products helps in managing the disease of the animals which is expected to boost the market Veterinary Syringes in the region. The veterinary syringes provide effective results for diabetes care which can increase the pet’s life.

The Veterinary Syringes Market in Asia Pacific is expected to grow at a higher rate due to adoption of animals which will increase the usage of Veterinary Syringes. In addition, countries such as India and China are expected to witness higher revenue growth during the forecast period.

Some of the major players in the Veterinary Syringes Market are Giordano Poultry Plast S.p.a., Hubert De backer nv, Intervet Inc., Nordson Corporation, Neogen Animal Safety, Becton, Dickinson and Company, genia, ThaMa-Vet Terumo Medical Corporation, SOL-Millennium, EXELINT among others. Moreover, the manufacturers and the producers are mainly focusing on strengthening the core competencies of their product portfolio.

Key data points covered in report

The report covers exhaustive analysis on:

• Veterinary Syringes Market by Product Type, End Users and region type
• Regional level market analysis of North America, Latin America, Europe, Asia Pacific, Middle East & Africa by Indications, End User and country segments
• Veterinary Syringes Dynamics & Opportunity Assessment
• Historical Actual Market Size, 2013 – 2017
• Veterinary Syringes Market Size & Forecast 2018-2028
• Veterinary Syringes Market Current Trends/Issues/Challenges
• Competition & Companies involved in Veterinary Syringes Market

Ask For Regional Data : https://www.futuremarketinsights.com/ask-regional/rep-gb-10238

Veterinary Syringes Market: Segmentation

Tentatively, Veterinary Syringes Market has been segmented on the basis of Product type, animal type, Dosage, End User and Geography.